Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.72 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.37 |
| ▸ | KHK | P50053 | 2/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714244 | 1.00 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL1094767 | 1.00 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL10265670 | 1.00 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1094729 | 0.98 | HTR6 (0.69) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1094728 | 0.98 | HTR6 (0.69) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL16633376 | 0.98 | HTR6 (0.69) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL238942 | 0.98 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL223255 | 0.98 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| SCHEMBL1447785 | 0.98 | HTR6 (0.75) | HTR6L3MBTL3L3MBTL1KHKMBTD1 | |
| Hydrochloric Acid SCHEMBL1814485 | 0.95 | HTR6 (0.72) | HTR6L3MBTL3L3MBTL1KHKMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114653318-B | Device and method for quickly constructing quinolone compound library | 广东工业大学 | 2024-02-13 | — | — | CN | claimed |
| CN-114653318-A | Device and method for quickly constructing quinolone compound library | 广东工业大学 | 2022-06-24 | — | — | CN | claimed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| CN-114653318-B | Device and method for quickly constructing quinolone compound library | 广东工业大学 | 2024-02-13 | — | — | CN | disclosed |
| CN-114653318-A | Device and method for quickly constructing quinolone compound library | 广东工业大学 | 2022-06-24 | — | — | CN | disclosed |
| US-20190016720-A1 | 7-OXO-6-(SULFOOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE CONTAINING COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | WOCKHARDT LIMITED (IN) | 2019-01-17 | — | — | US | disclosed |
| US-8829010-B2 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829010-B2 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829010-B2 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2718295-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | Pfizer Inc (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | HELAL CHRISTOPHER JOHN (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | HELAL CHRISTOPHER JOHN (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | HELAL CHRISTOPHER JOHN (US) | 2014-03-20 | — | — | US | disclosed |
| CN-103596956-A | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or cyp3A4 inhibitors | PFIZER | 2014-02-19 | — | — | CN | disclosed |
| WO-2012168817-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PFIZER INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168817-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PFIZER INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-1434774-A1 | 3-(4-SUBSTITUTED HETEROCYCLYL)-PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-6642232-B2 | Antitumor agents | SUGEN, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030130235-A1 | 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003031438-A1 | 3-[4-(SUBSTITUTED HETEROCYCLYL)-PYRROL-2-YLMETHYLIDENE]-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PDE12, PDE2A, CYP1A2 | HTR6 1044/4885L3MBTL3 4527/4885L3MBTL1 4605/4885 |
| US-20030130235-A1 | 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors | PDGFRB, PDGFRA, KDR | HTR6 540/4885L3MBTL3 4581/4885L3MBTL1 4717/4885 |
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR6 4845/4885L3MBTL3 2353/4885L3MBTL1 1876/4885 |
| US-20190016720-A1 | 7-OXO-6-(SULFOOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE CONTAINING COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | DDO, SPOUT1, SULT1E1 | HTR6 1736/4885L3MBTL3 3130/4885L3MBTL1 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.